National and Kapodistrian University of Athens
Διερεύνηση μεθόδων φαινοτυπικού ελέγχου για την ανίχνευση εκτεταμένου φάσματος β-λακταμασών στα gram- αρνητικά βακτήρια
Abstract
dc:descriptionResistance of the Gram negative bacteria to the third generation cephalosporins is a major public health issue worldwide, mostly due to the production of the Extended- Spectrum β-lactamases (ESBLs). This phenomenon was first detected in the 1980s but nowadays has gained endemic dimensions in several regions of the world. Extended-spectrum β-lactamases are mostly plasmid-mediated β-lactamases that efficiently hydrolyze oxyiminocephalosporins and monobactams, yet are inhibited by β-lactamase inhibitors such as clavulanate acid. The Clinical and Labarotary Standards Institute (CLSI) recommends a confirmatory combined-disk (CLSI ESBL Confirmatory Test, 2000) to confirm the production of the extended spectrum beta-lactamases in E.coli, Klebsiella spp, P.mirabilis. It consists of measuring the growth inhibitory zones around cefotaxime (CTX) and ceftazidime (CAZ) disks with or without clavulanate (CA).ESBLs, however, may also coexist with other β-lactamases types such as carbapenemases and AmpC-β-lactamases, which may also interfere with the interpretation of ESBL-detection methods since they also hydrolyze the β-lactams, resulting to the underestimation of the prevalence of ESBLs. There is a need, therefore, for an alternative method that can accurately detect ESBLs regardless of a possible coexistence of other types of β- lactamases. In an attempt to overcome the difficulties and unmask ESBL-production in presence of carbapenemases and AmpCs, we propose a modification of the CLSI ESBL Confirmatory Test .We have found that the CLSI ESBL Test could not identify the production of ESBLs in the majority of examined ESBL-producing isolates that also co-produce carbapenemases or AmpC-beta-lactamases. We further modified the CLSI ESBL Confirmatory Test by simultaneous addition of both 400mg boronic acid and 292mg EDTA on the antibiotic disks containing ceftazidime and cefotaxime with and without clavulanate acid, as these agents inhibit the enzymatic activity of carbapenemases and AmpCs. We hypothesized, therefore, that the addition of these inhibitors will reveal the covert production of ESBLs.A total of 368 non repetitive (one per patient) clinical isolates of Gram-negative bacteria were included in the study. They were recovered during 2007 to 2014 from seven Greek hospitals. The selected isolates were tested by determination of agar dilution MICs, phenotypic detection of carbapenemases and cephalosporinases and molecular typing methods (single- end και real -time PCRs). The PCR and sequencing analyses were employed for the identification of the ESBLs, KPCs, MBLs, AmpCs and OXA-48 genes. Specifically, 189 genotypically confirmed ESBL-positive isolates and 179 genotypically confirmed ESBL-negative isolates were included. Among the 189 ESBL-positive isolates, 118 were also simultaneous producers of carbapenemases or AmpCs. The collection consisted of 301 isolates of Enterobacteriaceae and 67 isolates of P.aeruginosa. The CLSI ESBL Confirmatory Test is performed in Enterobacteriaceae when no carbapenemases or AmpCs are coproduced. Phenotypic detection of ESBLs in P.aeruginosa remains challenging as there is no standardized phenotypic method.The aim of this thesis is to evaluate the proposed modified method not only in Enterobacteriaceae but also in P.aeruginosa. We employed the standard CLSI ESBL Confirmatory Test and the modified test at the 368 isolates of the study. The analysis of the results showed that the modified test was able to detect the production of ESBLs in the vast majority of ESBL-producers regardless of the underlying β-lactam resistance mechanism. Among Enterobacteriaceae ,the modified test was found able to detect almost all genotypically ESBL-positive isolates and did not give false-positive results for any of the ESBL-negative isolates. In contrast to the standard CLSI ESBL test , the modified test detectesd ESBLs among all KPC,NDM and AmpC producers as well the vast majority of VIM and KPC/VIM producers .The sensitivity of the modified test is 97,5% and the specificity is 100% . On the other hand, the sensitivity of the standard CLSI ESBL Confirmatory Test was 65,4% and the specificity was 97.1 % (It gave 4 gave false positive results).Among P.aeruginosa ,the modified test was found able to detect all genotypically ESBL-positive isolates and did not give false-positive results for any of the ESBL-negative isolates (sensitivity 100%,specificity 100%) . In contrast , the standard CLSI test detected 4 of the 10 VIM/ESBL producers and gave 3 false positive results. The the sensitivity of the standard CLSI ESBL Confirmatory Test is 70,3% and the specificity is 92,5 %.In conclusion, this thesis evaluated the modified test as a simple, in terms of easy application, and inexpensive method with high sensitivity and specificity, which can accurately detect the production of ESBLs regardless of a possible coexistence of other types of beta- lactamases. The modified method might guide theurapeutic options.It can also contribute to collection of the epidemiological data and the adequate application of infection control measures, particularly in countries of complex epidemiology regarding the dispersion of beta-lactamases
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Eugenia, Grivakou
- Γριβάκου, Ευγενία
Subjects
dc:subject × 20- Μικροβιακή αντοχή
- Β-λακταμάσες
- β-λακταμάσες εκτεταμένου φάσματος
- φαινοτυπικές μέθοδοι
- CLSI
- Εντεροβακτηριακά
- Pseudomonas aeruginosa
- Καρβαπενεμάσες
- AmpC-β-λακταμάσες
- Antimicrbial resistance
- β-lactamases
- Extended spectrum β-lactamases
- phenotypic methods
- Enterobacteriaceae
- Carbapenemases
- AmpC-β-lactamases
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43537